Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. announced adjustments to its 2025 A Share Option Incentive Scheme, reducing the number of participants from 251 to 235 and the total A Share Options from 26,175,871 to 25,965,871. These changes, approved by the Board of Directors and the Remuneration and Appraisal Committee, are not expected to materially impact the company’s financial condition or operations, and do not require further shareholder approval.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biotechnology company based in China, focusing on the development and commercialization of innovative therapeutics. The company operates in the biosciences industry, primarily offering biopharmaceutical products and services.
Average Trading Volume: 13,139,562
Technical Sentiment Signal: Buy
Current Market Cap: HK$42B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.